YZJ-0318

YZJ-0318 is a small molecule drug candidate developed as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), specifically targeting the EGFR T790M mutation. This mutation is associated with acquired resistance to earlier-generation EGFR inhibitors in non-small cell lung cancer (NSCLC). The drug was initially developed by Jiangsu Yangtze River Pharmaceutical Group and has been evaluated in early-phase clinical trials for advanced NSCLC patients harboring EGFR mutations, particularly those with the T790M resistance mutation. Its mechanism of action involves irreversible inhibition of mutant forms of the EGFR tyrosine kinase, thereby blocking downstream signaling pathways that drive tumor cell proliferation and survival[1][4].